Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
TTI-621 by Pfizer for Follicular Lymphoma: Likelihood of Approval
TTI-621 is under clinical development by Pfizer and currently in Phase II for Follicular Lymphoma. According to GlobalData, Phase II...
Data Insights
TTI-621 by Pfizer for Primary Mediastinal B-Cell Lymphoma: Likelihood of Approval
TTI-621 is under clinical development by Pfizer and currently in Phase II for Primary Mediastinal B-Cell Lymphoma. According to GlobalData,...